Is Bio­gen the most des­per­ate buy­er scout­ing the biotech mar­ket?

There are sev­er­al big play­ers in biotech who would clear­ly love to make a splashy ac­qui­si­tion. A rich Gilead ($GILD), now that the bloom is com­ing off its hep C rose, is one. Ab­b­Vie ($AB­BV), be­cause its last big ex­cit­ing ac­qui­si­tion – Stem­cen­trx – im­me­di­ate­ly lost lus­ter at AS­CO. Al­ler­gan ($AGN) has the mon­ey and a deal­mak­ing CEO who likes to think big.

And Pfiz­er ($PFE) makes the list, be­cause, well, you name it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.